AHRQ 30% FY 2003 Budget Increase To Be Urged By Friends Of Agency
This article was originally published in The Gray Sheet
Executive Summary
The Friends of the Agency for Healthcare Research and Quality plans to recommend an allocation of at least $390 mil. for the agency in support of AHRQ's role as an independent entity with purview over health services research
You may also be interested in...
FDA Centralization Plan Under Review; HHS Aiming For “One Clear Message”
Consolidation of HHS public affairs and legislative activities across the department will blunt the political impact of the incoming FDA commissioner, potentially allowing the position to focus on science policy and product review issues
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.